Adjuvant chemotherapy for resectable pancreatic ductal adenocarcinoma: a single-center retrospective study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Adjuvant chemotherapy improves survival after resection of pancreatic ductal adenocarcinoma (PDAC), but the comparative outcomes of gemcitabine monotherapy (G) and gemcitabine plus S-1 (GS) in routine practice remain uncertain. This study aimed to analyze the associations of chemotherapy regimen and treatment completion with survival. Methods We retrospectively evaluated patients undergoing curative-intent resection for PDAC at Peking University First Hospital between January 2010 and April 2022. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan–Meier analysis and multivariable Cox proportional hazards models. Sensitivity analyses included modeling chemotherapy initiation as a time-dependent exposure and comparing restricted mean survival time (RMST) between the G and GS groups over a 36-month horizon. Results The cohort included 245 patients, of whom 173 received postoperative chemotherapy; 46 received G and 90 received GS. Date-derived survival analyses included 242 evaluable patients. Median OS was 30.00 months (95% CI, 19.88–36.07) and median DFS was 15.93 months (95% CI, 12.52–24.57). For GS versus G, adjusted HRs were 1.28 (95% CI, 0.72–2.28) for OS and 1.36 (95% CI, 0.78–2.37) for DFS. Conclusions No significant differences in OS or DFS were observed between G and GS in this cohort. The exploratory associations between chemotherapy completion and survival need confirmation in studies that account for treatment timing and potential confounding.
Source: Frontiers in Oncology
Authors: Jianqiao Yang(Data curation, Formal analysis, Writing – original draft), Fusheng Zhang(Data curation, Investigation, Writing – review & editing), Xuewei Sun(Investigation, Validation, Writing – review & editing), Yiran Chen(Data curation, Validation, Writing – review & editing), Weikang Liu(Data curation, Investigation, Writing – review & editing), Yinmo Yang(Conceptualization, Supervision, Writing – review & editing), Yongsu Ma(Conceptualization, Methodology, Supervision, Writing – review & editing), Xiaodong Tian(Conceptualization, Investigation, Writing – original draft, Writing – review & editing)
Institution: Peking University First Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7235947889
